1. Home
  2. NTLA vs ETW Comparison

NTLA vs ETW Comparison

Compare NTLA & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • ETW
  • Stock Information
  • Founded
  • NTLA 2014
  • ETW 2005
  • Country
  • NTLA United States
  • ETW United States
  • Employees
  • NTLA N/A
  • ETW N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ETW Investment Managers
  • Sector
  • NTLA Health Care
  • ETW Finance
  • Exchange
  • NTLA Nasdaq
  • ETW Nasdaq
  • Market Cap
  • NTLA 794.5M
  • ETW 904.6M
  • IPO Year
  • NTLA 2016
  • ETW N/A
  • Fundamental
  • Price
  • NTLA $10.68
  • ETW $8.70
  • Analyst Decision
  • NTLA Buy
  • ETW
  • Analyst Count
  • NTLA 19
  • ETW 0
  • Target Price
  • NTLA $35.11
  • ETW N/A
  • AVG Volume (30 Days)
  • NTLA 4.9M
  • ETW 284.6K
  • Earning Date
  • NTLA 08-07-2025
  • ETW 01-01-0001
  • Dividend Yield
  • NTLA N/A
  • ETW 8.61%
  • EPS Growth
  • NTLA N/A
  • ETW N/A
  • EPS
  • NTLA N/A
  • ETW N/A
  • Revenue
  • NTLA $45,569,000.00
  • ETW N/A
  • Revenue This Year
  • NTLA N/A
  • ETW N/A
  • Revenue Next Year
  • NTLA N/A
  • ETW N/A
  • P/E Ratio
  • NTLA N/A
  • ETW N/A
  • Revenue Growth
  • NTLA N/A
  • ETW N/A
  • 52 Week Low
  • NTLA $5.90
  • ETW $6.96
  • 52 Week High
  • NTLA $28.18
  • ETW $8.49
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 69.70
  • ETW 70.48
  • Support Level
  • NTLA $8.98
  • ETW $8.28
  • Resistance Level
  • NTLA $11.08
  • ETW $8.55
  • Average True Range (ATR)
  • NTLA 0.69
  • ETW 0.07
  • MACD
  • NTLA 0.16
  • ETW 0.02
  • Stochastic Oscillator
  • NTLA 88.96
  • ETW 93.33

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.

Share on Social Networks: